Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb 1;85(Suppl 2):1–5. doi: 10.1054/bjoc.2001.1981

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women

W Jonat 1
PMCID: PMC2375170  PMID: 11900209

Abstract

Current standard adjuvant therapies for premenopausal women with early breast cancer include ovarian ablation by surgery or irradiation, chemotherapy and tamoxifen. The value of ovarian ablation in prolonging the survival of premenopausal patients with early breast cancer was clearly established by the analyses performed by the Early Breast Cancer Trialists' Collaborative Group in 1996. More recently, the value of ovarian suppression using the luteinizing hormone releasing hormone analogue goserelin as adjuvant therapy in pre-/perimenopausal women with early breast cancer has been confirmed in a series of studies involving over 8000 patients. The results from these studies provide evidence that goserelin, alone or in combination with tamoxifen, is at least as effective as cytotoxic chemotherapy in patients with hormone receptor-positive tumours and is effective when used after adjuvant chemotherapy. The use of goserelin in the management of early breast cancer presents an option which can avoid the side-effects experienced with cytotoxic chemotherapy and may offer unique benefits to premenopausal patients. The consolidation of these emerging results should help in defining the optimal role for goserelin in pre-/perimenopausal patients with early breast cancer. © 2001 Cancer Research Campaign

Keywords: adjuvant, early breast cancer, ovarian ablation, premenopausal, goserelin, Zoladex

Full Text

The Full Text of this article is available as a PDF (38.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebi S., Gelber S., Castiglione-Gertsch M., Gelber R. D., Collins J., Thürlimann B., Rudenstam C. M., Lindtner J., Crivellari D., Cortes-Funes H. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000 May 27;355(9218):1869–1874. doi: 10.1016/s0140-6736(00)02292-3. [DOI] [PubMed] [Google Scholar]
  2. Blamey R. W., Jonat W., Kaufmann M., Bianco A. R., Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer. 1992;28A(4-5):810–814. doi: 10.1016/0959-8049(92)90120-q. [DOI] [PubMed] [Google Scholar]
  3. Blamey R. W., Jonat W., Kaufmann M., Bianco A. R., Namer M. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer. 1993;29A(10):1498–1498. doi: 10.1016/0959-8049(93)90031-a. [DOI] [PubMed] [Google Scholar]
  4. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Sismondi P., Giai M., Genta F., Pacini P., Distante V. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it. J Clin Oncol. 2000 Jul;18(14):2718–2727. doi: 10.1200/JCO.2000.18.14.2718. [DOI] [PubMed] [Google Scholar]
  5. Boccardo F., Rubagotti A., Perrotta A., Amoroso D., Balestrero M., De Matteis A., Zola P., Sismondi P., Francini G., Petrioli R. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994 Apr;5(4):337–342. doi: 10.1093/oxfordjournals.annonc.a058837. [DOI] [PubMed] [Google Scholar]
  6. Castiglione-Gertsch M., Gelber R. D., O'Neill A., Coates A. S., Goldhirsch A. Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group. Eur J Cancer. 2000 Mar;36(4):549–550. doi: 10.1016/s0959-8049(00)00006-x. [DOI] [PubMed] [Google Scholar]
  7. Furr B. J. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res. 1989;32 (Suppl 1):86–92. doi: 10.1159/000181318. [DOI] [PubMed] [Google Scholar]
  8. Goodwin P. J., Ennis M., Pritchard K. I., Trudeau M., Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999 Aug;17(8):2365–2370. doi: 10.1200/JCO.1999.17.8.2365. [DOI] [PubMed] [Google Scholar]
  9. Jonat W., Kaufmann M., Blamey R. W., Howell A., Collins J. P., Coates A., Eiermann W., Jänicke F., Njordenskold B., Forbes J. F. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995;31A(2):137–142. doi: 10.1016/0959-8049(94)00415-2. [DOI] [PubMed] [Google Scholar]
  10. Kroman N., Jensen M. B., Wohlfahrt J., Mouridsen H. T., Andersen P. K., Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000 Feb 19;320(7233):474–478. doi: 10.1136/bmj.320.7233.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pfeilschifter J., Diel I. J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000 Apr;18(7):1570–1593. doi: 10.1200/JCO.2000.18.7.1570. [DOI] [PubMed] [Google Scholar]
  12. Pujol P., Daures J. P., Thezenas S., Guilleux F., Rouanet P., Grenier J. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer. 1998 Aug 15;83(4):698–705. [PubMed] [Google Scholar]
  13. Taylor C. W., Green S., Dalton W. S., Martino S., Rector D., Ingle J. N., Robert N. J., Budd G. T., Paradelo J. C., Natale R. B. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar;16(3):994–999. doi: 10.1200/JCO.1998.16.3.994. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES